Vaxdyn, S. L. news
The experts of the Anti-Microbial Resistance (AMR) world, including Vaxdyn’s researchers, have been warning about the entrance into a post-antibiotic era or the occurrence of a silent pandemic for years. However, the general public, including health practitioners, did not understand the message or underscored the magnitude of the problem.
Recently, a vast network of AMR experts around the world, including bacteriologists, epidemiologists, data analysts, and public health manager
In an oral presentation within the track “AMR & Bacterial Vaccines”, chaired by Dr Jan Poolman (Bacterial Vaccine Discovery and Early Development, Janssen), Dr. Infante showed how Vaxdyn’s technology can deliver endotoxin-free inactivated whole cell vaccines presenting outer-membrane proteins of different bacteria in the surface, therefore raising immunity against different bacteria with only one immunogen. The KapaVax candidate targets include three of the
CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia. Vaxdyn is the first Spanish biotech to be funded by CARB-X, a non-profit partnership investing $500 million in the development of innovative vaccines, antibiotics and rapid diagnostics to fight drug-resistant bacteria around the world.
&ldq
The project “AMReady: Development and manufacturing of vaccines for alleviation and preparedness for anti-microbial resistance global health crisis”, to be executed in 2021-2024 with a total budget of 1.4 million euro has been awarded funding by the competitive program Lineas Estratégicas de Colaboración Público-Privada 2021 of the State Research Agency of the Spanish Ministry of Science and Innovation, in the Recovery and Resili
The development of a technology able to deliver multi-pathogen vaccine candidates against the most worrisome antibiotic-resistant bacteria has attracted new investors to Vaxdyn, the Portuguese venture capital firm Bionova Capital and the international cross-sectorial Arquimea Group. Each of the new investors has joined the capital of Vaxdyn with the acquisition of shares valued €300,000 in two tranches.
Bionova Capital is a leading venture capital firm investing in